Emily Oldshue brings a leading transactional lawyer's perspective to mergers and acquisitions. Her insight into how to navigate challenging business issues and complex transactions has made her a trusted advisor for a diverse base of public and private companies, investment banks and private equity funds.
In M&A, clients benefit from the breadth of Emily’s experience, which includes significant cross-border work, carveouts, spin-offs, majority and minority investments, joint ventures, divestitures, bolt-ons and a variety of other complex strategic transactions in addition to regular-way public and private M&A.
In addition to her transactional work, Emily counsels clients on ongoing corporate governance matters, including ESG.
Experience
Represented public and private acquirers, sellers and targets in domestic and cross-border M&A and private equity transactions.
- M&A
- National Amusements Inc in its pending sale to affiliates of Skydance Media in concert with the merger of Skydance Media with Paramount Global
- Pfizer in its acquisition of Biohaven Pharmaceutical (BVI), immediately following a spin-off of non-core Biohaven assets
- Pfizer in its acquisition of Arena Pharmaceuticals
- Pfizer in its acquisition of Trillium Therapeutics (Canada)
- Merck in its acquisition of Abceutics
- Medtronic in its divestiture of investments in more than 70 portfolio companies
- Medtronic in its acquisition of Mazor Robotics (Israel)
- Becton Dickinson in its acquisition of the Critical Care business of Edwards Lifesciences
- Becton Dickinson in its acquisition of the MedKeeper business of Grifols (Spain)
- Becton Dickinson in its acquisition of NAT Diagnostics
- Becton Dickinson in its acquisition of the medical business of CUBEX
- Becton Dickinson in its acquisition of GenCell Biosystems (Ireland)
- BMS in its option to acquire Serac Biosciences (Switzerland)
- KARL STORZ in its acquisition of Asensus Surgical (Germany)
- AskBio in its dual-track process resulting in its sale to Bayer
- Aptalis Holdings in its dual-track process resulting in its sale to Forest Laboratories
- Consortium of Boston hospitals in transactions involving the sale of a tri-gen power plant servicing Longwood Medical and Academic Area institutions
- Sandbridge Acquisition Corporation in its business combination with Owlet
- Aegerion Pharmaceuticals in its merger of equals with Novelion Therapeutics (Canada)
- National Amusements in an asset sale transaction
- Private Equity
- TriArtisan Capital Advisors in its acquisition of a majority position in TGI Friday’s
- BlackRock in more than twenty co-investment transactions across industries, including investments in American Express Global Business Travel and Alibaba
- TPG Capital in its acquisition of J. Crew
- Symmetry Surgical in its sale to RoundTable Healthcare Partners
- Bain Capital Ventures in successive investments in Thorley Industries
Advised issuers, underwriters and initial purchasers in IPOs, follow-on offerings and registered and unregistered note offerings across a variety of sectors, including life sciences, consumer, climate and clean energy, food and beverage, financial services, technology and manufacturing. Representative experience includes offerings by
- Autolus Therapeutics (England and Wales)
- CRISPR Therapeutics (Switzerland)
- HOOKIPA Pharma (Austria)
- Fulcrum Therapeutics
- Karyopharm Therapeutics
- Domino’s
- Wendy’s
- Dunkin’ Brands
- Sandbridge Acquisition Corporation
- Sandbridge X2 Corp.
- USHG Acquisition Corp. (Union Square Hospitality Group)
- Climate Change Crisis Real Impact I Acquisition Corporation
- Climate Real Impact Solutions II Acquisition Corporation
- Freedom Acquisition I Corp. (Cayman)
- NextGen Acquisition Corp. (Cayman)
- NextGen Acquisition Corp. II (Cayman)
- Tekni-Plex
- Ellucian
- Norcraft Companies
- PennantPark Investment Corp.